Hemoglobinopathies- Market Insights, Epidemiology and Market Forecast 2028

Table of Contents

Chapter 1 Overview of Hemoglobinopathies

• 1.1 Definition of Hemoglobinopathies in This Report
• 1.2 Commercial Types of Hemoglobinopathies
  • 1.2.1 Thalassemia
  • 1.2.2 Sickle Cell Disease
  • 1.2.3 Other Hb Variants Diseases
• 1.3 Downstream Application of Hemoglobinopathies
  • 1.3.1 Blood Testing
  • 1.3.2 Genetic Testing
  • 1.3.3 Pre-Implantation Genetic Diagnosis (PGD)
  • 1.3.4 Others
• 1.4 Development History of Hemoglobinopathies
• 1.5 Market Status and Trend of Hemoglobinopathies 2013-2023
  • 1.5.1 Global Hemoglobinopathies Market Status and Trend 2013-2023
  • 1.5.2 Regional Hemoglobinopathies Market Status and Trend 2013-2023

Chapter 2 Global Market Status and Forecast by Regions

• 2.1 Market Development of Hemoglobinopathies 2013-2017
• 2.2 Production Market of Hemoglobinopathies by Regions
  • 2.2.1 Production Volume of Hemoglobinopathies by Regions
  • 2.2.2 Production Value of Hemoglobinopathies by Regions
• 2.3 Demand Market of Hemoglobinopathies by Regions
• 2.4 Production and Demand Status of Hemoglobinopathies by Regions
  • 2.4.1 Production and Demand Status of Hemoglobinopathies by Regions 2013-2017
  • 2.4.2 Import and Export Status of Hemoglobinopathies by Regions 2013-2017

Chapter 3 Global Market Status and Forecast by Types

• 3.1 Production Volume of Hemoglobinopathies by Types
• 3.2 Production Value of Hemoglobinopathies by Types
• 3.3 Market Forecast of Hemoglobinopathies by Types

Chapter 4 Global Market Status and Forecast by Downstream Industry

• 4.1 Demand Volume of Hemoglobinopathies by Downstream Industry
• 4.2 Market Forecast of Hemoglobinopathies by Downstream Industry

Chapter 5 Market Driving Factor Analysis of Hemoglobinopathies

• 5.1 Global Economy Situation and Trend Overview
• 5.2 Hemoglobinopathies Downstream Industry Situation and Trend Overview

Chapter 6 Hemoglobinopathies Market Competition Status by Major Manufacturers

• 6.1 Production Volume of Hemoglobinopathies by Major Manufacturers
• 6.2 Production Value of Hemoglobinopathies by Major Manufacturers
• 6.3 Basic Information of Hemoglobinopathies by Major Manufacturers
  • 6.3.1 Headquarters Location and Established Time of Hemoglobinopathies Major Manufacturer
  • 6.3.2 Employees and Revenue Level of Hemoglobinopathies Major Manufacturer
• 6.4 Market Competition News and Trend
  • 6.4.1 Merger, Consolidation or Acquisition News
  • 6.4.2 Investment or Disinvestment News
  • 6.4.3 New Product Development and Launch

Chapter 7 Hemoglobinopathies Major Manufacturers Introduction and Market Data

• 7.1 Emmaus Life Sciences Inc.
  • 7.1.1 Company profile
  • 7.1.2 Representative Hemoglobinopathies Product
  • 7.1.3 Hemoglobinopathies Sales, Revenue, Price and Gross Margin of Emmaus Life Sciences Inc.
• 7.2 Prolong Pharmaceuticals
  • 7.2.1 Company profile
  • 7.2.2 Representative Hemoglobinopathies Product
  • 7.2.3 Hemoglobinopathies Sales, Revenue, Price and Gross Margin of Prolong Pharmaceuticals
• 7.3 Sangamo Therapeutics Inc.
  • 7.3.1 Company profile
  • 7.3.2 Representative Hemoglobinopathies Product
  • 7.3.3 Hemoglobinopathies Sales, Revenue, Price and Gross Margin of Sangamo Therapeutics Inc.
• 7.4 Alnylam Pharmaceuticals
  • 7.4.1 Company profile
  • 7.4.2 Representative Hemoglobinopathies Product
  • 7.4.3 Hemoglobinopathies Sales, Revenue, Price and Gross Margin of Alnylam Pharmaceuticals
• 7.5 Gamida Cell
  • 7.5.1 Company profile
  • 7.5.2 Representative Hemoglobinopathies Product
  • 7.5.3 Hemoglobinopathies Sales, Revenue, Price and Gross Margin of Gamida Cell
• 7.6 Sanofi
  • 7.6.1 Company profile
  • 7.6.2 Representative Hemoglobinopathies Product
  • 7.6.3 Hemoglobinopathies Sales, Revenue, Price and Gross Margin of Sanofi
• 7.7 Bluebird Bio
  • 7.7.1 Company profile
  • 7.7.2 Representative Hemoglobinopathies Product
  • 7.7.3 Hemoglobinopathies Sales, Revenue, Price and Gross Margin of Bluebird Bio
• 7.8 Global Blood Therapeutics
  • 7.8.1 Company profile
  • 7.8.2 Representative Hemoglobinopathies Product
  • 7.8.3 Hemoglobinopathies Sales, Revenue, Price and Gross Margin of Global Blood Therapeutics
• 7.9 Celgene Corporation
  • 7.9.1 Company profile
  • 7.9.2 Representative Hemoglobinopathies Product
  • 7.9.3 Hemoglobinopathies Sales, Revenue, Price and Gross Margin of Celgene Corporation

Chapter 8 Upstream and Downstream Market Analysis of Hemoglobinopathies

• 8.1 Industry Chain of Hemoglobinopathies
• 8.2 Upstream Market and Representative Companies Analysis
• 8.3 Downstream Market and Representative Companies Analysis

Chapter 9 Cost and Gross Margin Analysis of Hemoglobinopathies

• 9.1 Cost Structure Analysis of Hemoglobinopathies
• 9.2 Raw Materials Cost Analysis of Hemoglobinopathies
• 9.3 Labor Cost Analysis of Hemoglobinopathies
• 9.4 Manufacturing Expenses Analysis of Hemoglobinopathies

Chapter 10 Marketing Status Analysis of Hemoglobinopathies

• 10.1 Marketing Channel
  • 10.1.1 Direct Marketing
  • 10.1.2 Indirect Marketing
  • 10.1.3 Marketing Channel Development Trend
• 10.2 Market Positioning
  • 10.2.1 Pricing Strategy
  • 10.2.2 Brand Strategy
  • 10.2.3 Target Client
• 10.3 Distributors/Traders List

Chapter 11 Report Conclusion

Chapter 12 Research Methodology and Reference

• 12.1 Methodology/Research Approach
  • 12.1.1 Research Programs/Design
  • 12.1.2 Market Size Estimation
  • 12.1.3 Market Breakdown and Data Triangulation
• 12.2 Data Source
  • 12.2.1 Secondary Sources
  • 12.2.2 Primary Sources